Gaby L. Longsworth Ph.D., Esq.

Sterne, Kessler, Goldstein & Fox P.L.L.C.
Longsworth, Gaby

Gaby L. Longsworth is a Director in the Biotechnology/Chemical Group of Sterne, Kessler, Goldstein & Fox P.L.L.C. in Washington, D.C. and serves as a member of the advisory board of Bloomberg BNA's Pharmaceutical Law & Industry Report. Dr. Longsworth is sought out by both innovator and generic pharmaceutical companies for her insights and knowledge of IP and brand product lifecycle management strategies. She counsels innovator pharmaceutical clients from around the world in all areas of patent procurement, including domestic and foreign patent preparation, and lifecycle management strategies.

A large part of Dr. Longsworth's practice is focused on representing international and domestic generic pharmaceutical companies in patent cases involving Abbreviated New Drug Applications (ANDAs) that include a Paragraph IV (pIV) certification to one or more Orange Book listed patents. She has provided strategic and technical advice in multiple ANDA patent infringement cases brought under the Hatch-Waxman Act. Dr. Longsworth has significant experience counseling clients on pIV filing strategies, including assessing the impact of data exclusivity, forfeiture issues (pre-MMA and post-MMA), label carve outs, and Patent Term Extensions (PTE).

Dr. Longsworth earned her B.S. from the Florida Institute of Technology, her Ph.D. from The Johns Hopkins University, and her J.D. from Georgetown University.